152 related articles for article (PubMed ID: 35352847)
1. Shrinkage versus fragmentation response in neoadjuvantly treated oesophageal adenocarcinoma: significant prognostic relevance.
Graham Martinez C; Kus Öztürk S; Al-Kaabi A; Valkema MJ; Bokhorst JM; Rosman C; Rütten H; Wauters CAP; Doukas M; van Lanschot JJ; Siersema PD; Nagtegaal ID; van der Post RS
Histopathology; 2022 May; 80(6):982-994. PubMed ID: 35352847
[TBL] [Abstract][Full Text] [Related]
2. Relevance of shrinkage versus fragmented response patterns in rectal cancer.
Kus Ozturk S; Graham Martinez C; Sheahan K; Winter DC; Aherne S; Ryan ÉJ; van de Velde CJ; Marijnen CA; Hospers GA; Roodvoets AG; Doukas M; Mens D; Verhoef C; van der Post RS; Nagtegaal ID
Histopathology; 2023 Dec; 83(6):870-879. PubMed ID: 37609761
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant chemoradiation for patients with advanced oesophageal cancer - which response grading system best impacts prognostic discrimination?
Puetz K; Bollschweiler E; Semrau R; Mönig SP; Hölscher AH; Drebber U
Histopathology; 2019 Apr; 74(5):731-743. PubMed ID: 30636069
[TBL] [Abstract][Full Text] [Related]
4. High CD8
Koemans WJ; van Dieren JM; van den Berg JG; Meijer GA; Snaebjornsson P; Chalabi M; Lecot F; Riedl R; Krijgsman O; Hofland I; Broeks A; Voncken FEM; Peppelenbosch MP; Sosef MN; van Sandick JW; Kodach LL
Histopathology; 2021 Aug; 79(2):238-251. PubMed ID: 33660299
[TBL] [Abstract][Full Text] [Related]
5. Surgical resection after neoadjuvant chemoradiation for oesophageal adenocarcinoma: what is the optimal timing?
Ranney DN; Mulvihill MS; Yerokun BA; Fitch Z; Sun Z; Yang CF; D'Amico TA; Hartwig MG
Eur J Cardiothorac Surg; 2017 Sep; 52(3):543-551. PubMed ID: 28498967
[TBL] [Abstract][Full Text] [Related]
6. Chemoradiation for oesophageal cancer: the choice of treatment modality.
Kitti PM; Faltinova M; Kauppi J; Räsänen J; Saarto T; Seppälä T; Anttonen AM
Radiat Oncol; 2023 May; 18(1):93. PubMed ID: 37259100
[TBL] [Abstract][Full Text] [Related]
7. The effectiveness of neoadjuvant chemoradiotherapy in oesophageal adenocarcinoma with presence of extracellular mucin, signet-ring cells, and/or poorly cohesive cells.
Valkema MJ; Vos AM; van der Post RS; Ooms AH; Oudijk L; Eyck BM; Lagarde SM; Wijnhoven BP; Klarenbeek BR; Rosman C; van Lanschot JJB; Doukas M
J Pathol Clin Res; 2023 Jul; 9(4):322-335. PubMed ID: 36971406
[TBL] [Abstract][Full Text] [Related]
8. The prognostic and potentially predictive value of the Laurén classification in oesophageal adenocarcinoma.
van der Kaaij RT; Snaebjornsson P; Voncken FE; van Dieren JM; Jansen EP; Sikorska K; Cats A; van Sandick JW
Eur J Cancer; 2017 May; 76():27-35. PubMed ID: 28262585
[TBL] [Abstract][Full Text] [Related]
9. Artificial intelligence for tumour tissue detection and histological regression grading in oesophageal adenocarcinomas: a retrospective algorithm development and validation study.
Tolkach Y; Wolgast LM; Damanakis A; Pryalukhin A; Schallenberg S; Hulla W; Eich ML; Schroeder W; Mukhopadhyay A; Fuchs M; Klein S; Bruns C; Büttner R; Gebauer F; Schömig-Markiefka B; Quaas A
Lancet Digit Health; 2023 May; 5(5):e265-e275. PubMed ID: 37100542
[TBL] [Abstract][Full Text] [Related]
10. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial].
Tian Y; Wang Q; Wang J; Qiao XY; Zhang J; Lin YC; Li Y; Fan LQ; Yang PG; Zhao Q
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):128-137. PubMed ID: 33508918
[No Abstract] [Full Text] [Related]
11. Value of CT-PET after neoadjuvant chemoradiation in the prediction of histological tumour regression, nodal status and survival in oesophageal adenocarcinoma.
Elliott JA; O'Farrell NJ; King S; Halpenny D; Malik V; Muldoon C; Johnston C; Reynolds JV
Br J Surg; 2014 Dec; 101(13):1702-11. PubMed ID: 25351460
[TBL] [Abstract][Full Text] [Related]
12. Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus.
Noble F; Nolan L; Bateman AC; Byrne JP; Kelly JJ; Bailey IS; Sharland DM; Rees CN; Iveson TJ; Underwood TJ; Bateman AR
World J Gastroenterol; 2013 Dec; 19(48):9282-93. PubMed ID: 24409055
[TBL] [Abstract][Full Text] [Related]
13. Radiation dose and pathological response in oesophageal cancer patients treated with neoadjuvant chemoradiotherapy followed by surgery: a multi-institutional analysis.
Thomas M; Borggreve AS; van Rossum PSN; Perneel C; Moons J; Van Daele E; van Hillegersberg R; Deng W; Pattyn P; Mook S; Boterberg T; Ruurda JP; Nafteux P; Lin SH; Haustermans K
Acta Oncol; 2019 Oct; 58(10):1358-1365. PubMed ID: 31432736
[No Abstract] [Full Text] [Related]
14. Perioperative chemotherapy vs. neoadjuvant chemoradiation in gastroesophageal junction adenocarcinoma : A population-based evaluation of the Munich Cancer Registry.
Münch S; Habermehl D; Agha A; Belka C; Combs SE; Eckel R; Friess H; Gerbes A; Nüssler NC; Schepp W; Schmid RM; Schmitt W; Schubert-Fritschle G; Weber B; Werner J; Engel J
Strahlenther Onkol; 2018 Feb; 194(2):125-135. PubMed ID: 29071366
[TBL] [Abstract][Full Text] [Related]
15. Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study.
Noordman BJ; Spaander MCW; Valkema R; Wijnhoven BPL; van Berge Henegouwen MI; Shapiro J; Biermann K; van der Gaast A; van Hillegersberg R; Hulshof MCCM; Krishnadath KK; Lagarde SM; Nieuwenhuijzen GAP; Oostenbrug LE; Siersema PD; Schoon EJ; Sosef MN; Steyerberg EW; van Lanschot JJB;
Lancet Oncol; 2018 Jul; 19(7):965-974. PubMed ID: 29861116
[TBL] [Abstract][Full Text] [Related]
16. P53 and SOX2 Protein Expression Predicts Esophageal Adenocarcinoma in Response to Neoadjuvant Chemoradiotherapy.
van Olphen SH; Biermann K; Shapiro J; Wijnhoven BP; Toxopeus EL; van der Gaast A; Stoop HA; van Lanschot JJ; Spaander MC; Bruno MJ; Looijenga LH
Ann Surg; 2017 Feb; 265(2):347-355. PubMed ID: 28059963
[TBL] [Abstract][Full Text] [Related]
17. Residual esophageal cancer after neoadjuvant chemoradiotherapy frequently involves the mucosa and submucosa.
Shapiro J; ten Kate FJ; van Hagen P; Biermann K; Wijnhoven BP; van Lanschot JJ
Ann Surg; 2013 Nov; 258(5):678-88; discussion 688-9. PubMed ID: 24096766
[TBL] [Abstract][Full Text] [Related]
18. Oncological outcomes of standard versus prolonged time to surgery after neoadjuvant chemoradiotherapy for oesophageal cancer in the multicentre, randomised, controlled NeoRes II trial.
Nilsson K; Klevebro F; Sunde B; Rouvelas I; Lindblad M; Szabo E; Halldestam I; Smedh U; Wallner B; Johansson J; Johnsen G; Aahlin EK; Johannessen HO; Alexandersson von Döbeln G; Hjortland GO; Wang N; Shang Y; Borg D; Quaas A; Bartella I; Bruns C; Schröder W; Nilsson M
Ann Oncol; 2023 Nov; 34(11):1015-1024. PubMed ID: 37657554
[TBL] [Abstract][Full Text] [Related]
19. Time interval between neoadjuvant chemoradiotherapy and surgery for oesophageal or junctional cancer: A nationwide study.
van der Werf LR; Dikken JL; van der Willik EM; van Berge Henegouwen MI; Nieuwenhuijzen GAP; Wijnhoven BPL;
Eur J Cancer; 2018 Mar; 91():76-85. PubMed ID: 29353163
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy analysis of neoadjuvant chemoradiotherapy combined with total pelvic exenteration in the treatment of primary T4b rectal cancer].
Wu T; Wen L; Zhang J; Wu Y; Jiang Y; Chen G; Wang X; Huang S; Wan Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jan; 22(1):59-65. PubMed ID: 30703795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
